西达基奥仑赛治疗高危冒烟型多发性骨髓瘤的2期CAR-PRISM试验
这项2期研究纳入20例高危冒烟型多发性骨髓瘤患者,未接受诱导或桥接治疗,直接给予西达基奥仑赛(cilta-cel)0.3-0.5×10^6或>0.5×10^6活CAR+ T细胞/kg。主要终点为剂量限制性毒性和治疗相关不良事件,次要终点包括缓解和MRD阴性。结果显示无剂量限制性毒性,所有患者2个月内达MRD阴性(10^-6)并持续保持,未观察到疾病进展或死亡。
要点
- 高危冒烟型骨髓瘤患者不接受诱导治疗直接输注cilta-cel,无剂量限制性毒性。
- 所有20例患者在2个月内达MRD阴性(10^-6)并持续维持,中位随访15.3个月无进展或死亡。
- 细胞因子释放综合征全部为1/2级,非免疫效应细胞相关神经毒性7例,其中4例颅神经麻痹完全缓解。
核心结论
- 西达基奥仑赛在不经诱导治疗的高危冒烟型多发性骨髓瘤中产生快速、深度且持续的MRD阴性缓解。
- 毒性特征与西达基奥仑赛已知安全性一致,未出现剂量限制性毒性。
研究设计与样本
- 2期临床试验(CAR-PRISM,NCT05767359),入组高危冒烟型多发性骨髓瘤患者。
- 患者接受西达基奥仑赛0.3-0.5×10^6或>0.5×10^6活CAR+ T细胞/kg,无诱导或桥接治疗;骨髓受累>40%者排除。
- 截至2026年2月11日共20例患者接受治疗;主要终点为剂量限制性毒性和治疗相关不良事件。
主要发现
- 无剂量限制性毒性发生。
- 不良事件包括一过性血细胞减少(90%为3/4级)和细胞因子释放综合征(100%为1/2级)。
- 非免疫效应细胞相关神经毒性综合征神经系统毒性事件发生于7例患者,其中4例为完全缓解的颅神经麻痹,3例有持续1级症状。
- 中位随访15.3个月,所有患者2个月内达MRD阴性(10^-6)并持续保持MRD阴性。
关键数值与推荐
- 剂量:西达基奥仑赛0.3-0.5×10^6或>0.5×10^6活CAR+ T细胞/kg。
- 主要终点:剂量限制性毒性和治疗相关不良事件;次要终点:缓解和MRD阴性。
- MRD阴性定义:10^-6,所有患者2个月内达到并持续。
临床怎么用
- 高危冒烟型骨髓瘤患者可考虑不经诱导治疗直接接受西达基奥仑赛治疗,以实现深度MRD阴性缓解。
- 治疗中需监测血细胞减少、细胞因子释放综合征及神经系统毒性,多数事件为低级别且可缓解。
局限性
- 样本量较小(20例),随访时间较短(中位15.3个月)。
- 为单臂2期试验,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-risk smoldering multiple myeloma (HR-SMM) carries an increased risk of progression to multiple myeloma, making it an ideal setting to test whether chimeric antigen receptor (CAR) T cell therapy can achieve curative outcomes. Here in this phase 2 study, patients with HR-SMM received ciltacabtagene autoleucel (cilta-cel) at 0.3-0.5 × 106 or >0.5 × 106 viable CAR+ T cells per kilogram without induction or bridging therapy. Patients with >40% marrow involvement were excluded. Primary endpoints were dose-limiting toxicities (DLTs) and treatment-emergent adverse events; secondary endpoints included response and minimal residual disease (MRD) negativity. As of 11 February 2026, 20 patients had been treated. The trial met the prespecified endpoints. No DLTs occurred. Adverse events included transient cytopenias (90% grade 3/4) and cytokine release syndrome (100% grade 1/2). Non-immune effector cell-associated neurotoxicity syndrome neurologic toxicities (NINTs) occurred in seven patients, with four comprising cranial nerve palsies that completely resolved. Three patients had persistent grade 1 symptoms. At a median follow-up of 15.3 months, all patients achieved MRD negativity 10-6 by 2 months and have remained MRD negative. Sixteen patients with follow-up >6 months achieved a complete response; no progression or deaths were observed. Cilta-cel produced rapid, deep, sustained MRD-negative responses in HR-SMM without induction therapy. Toxicities were consistent with the safety profile of cilta-cel. ClinicalTrials.gov: NCT05767359 .
引用
- Nadeem O, Cordas Dos Santos DM, Nikiforow S, et al. Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial. Nat Med. 2026. PMID: 42010117. doi:10.1038/s41591-026-04365-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。